For the quarter ended March 2026, ANI Pharmaceuticals (ANIP Quick QuoteANIP - Free Report) reported revenue of $237.46 million, up 20.5% over the same period last year. EPS came in at $2.05, compared to $1.70 in the year-ago quarter.

The reported revenue represents a surprise of +15.61% over the Zacks Consensus Estimate of $205.41 million. With the consensus EPS estimate being $1.28, the EPS surprise was +60.16%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how ANI performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Revenues- Rare Disease and Brands- Cortrophin Gel: $75.12 million versus the four-analyst average estimate of $75.9 million. The reported number represents a year-over-year change of +42.1%.
• Total Net Revenues- Rare Disease: $94.37 million versus the four-analyst average estimate of $93.56 million.
• Net Revenues- Rare Disease and Brands- ILUVIEN and YUTIQ: $19.26 million versus the four-analyst average estimate of $17.66 million. The reported number represents a year-over-year change of +19.5%.
• Net Revenues- Generic pharmaceutical products: $105.4 million versus the three-analyst average estimate of $94.56 million. The reported number represents a year-over-year change of +6.8%.

View all Key Company Metrics for ANI here>>>

Shares of ANI have returned +4.7% over the past month versus the Zacks S&P 500 composite's +11% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.